A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320

William TownsendCancer Research UK and University College London Cancer Trials Centre, London, UK;

Rod J. JohnsonThe Leeds Teaching Hospitals NHS Trust, Leeds, UK;

Bryson T. PottingerRoyal Cornwall Hospitals NHS Trust, Truro, UK;

Nicholas CounsellCancer Research UK and University College London Cancer Trials Centre, London, UK;

Paul SmithCancer Research UK and University College London Cancer Trials Centre, London, UK;

Humra ChadwickCancer Research UK and University College London Cancer Trials Centre, London, UK;

Katy EvansDepartment of Haematology, Royal Devon and Exeter NHS Foundation Trust, Exeter, DevonEX2 5AD, UK

Caroline WickhamDepartment of Haematology, Royal Devon and Exeter NHS Foundation Trust, Exeter, DevonEX2 5AD, UK

Claudius E RudinDepartment of Haematology, Royal Devon and Exeter NHS Foundation Trust, Exeter, DevonEX2 5AD, UKCorrespondence[email protected]

& On behalf of the UK NCRI Lymphoma Clinical Studies Group show all

Click to increase image sizeClick to decrease image size

Acknowledgements

We gratefully acknowledge the patients who participated in this trial, the local investigators and site staff. In addition, we would like to thank the Independent Data Monitoring Committee, the Trial Steering Committee, Cancer Research UK who provided funding, Lymphoma Research Trust and the NCRI Lymphoma clinical studies group.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2015.1133814.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320

Potential conflict of interest

Information for

Open access

Opportunities

Help and information

A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature